Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers

Nasim Mavaddat; Antonis C. Antoniou; Thea M. Mooij; Maartje J. Hooning; Bernadette A. Heemskerk-Gerritsen; Catherine Noguès; Lilian Laborde; Emmanuel Breysse; Dominique Stoppa-Lyonnet; Marion Gauthier-Villars; Bruno Buecher; Olivier Caron; Emmanuelle Fourme-Mouret; Jean Pierre Fricker; Christine Lasset; Valérie Bonadona; Pascaline Berthet; Laurence Faivre; Elisabeth Luporsi; Véronique Mari; Laurence Gladieff; Paul Gesta; Hagay Sobol; François Eisinger; Catherine Noguès; Michel Longy; Catherine Dugast; Chrystelle Colas; Isabelle Coupier; Pascal Pujol; Carole Corsini; Alain Lortholary; Philippe Vennin; Claude Adenis; Tan Dat Nguyen; Capucine Delnatte; Julie Tinat; Isabelle Tennevet; Jean Marc Limacher; Christine Maugard; Yves Jean Bignon; Liliane Demange; Clotilde Penet; Hélène Dreyfus; Odile Cohen-Haguenauer; Laurence Venat-Bouvet; Dominique Leroux; Hélène Dreyfus; Hélène Zattara-Cannoni; Sandra Fert-Ferrer; Odile Bera; Catherine Noguès; Marion Gauthier-Villars; Olivier Caron; Paul Gesta; Pascal Pujol; Alain Lortholary; Steve Ellis; Daniel Barrowdale; Debra Frost; D. Gareth Evans; Louise Izatt; Julian Adlard; Ros Eeles; Carole Brewer; Marc Tischkowitz; Alex Henderson; Jackie Cook; Diana Eccles; F. B.L. Hogervorst; J. M. Collée; C. J. Van Asperen; A. R. Mensenkamp; M. G.E.M. Ausems; H. E.J. Meijers-Heijboer; K. Van Engelen; M. J. Blok; J. C. Oosterwijk; J. Verloop; E. Van Den Broek; Klaartje Van Engelen; Marian J.E. Mourits; Margreet G.E.M. Ausems; Linetta B. Koppert; John L. Hopper; Esther M. John; Wendy K. Chung; Irene L. Andrulis; Mary B. Daly; Saundra S. Buys; Javier Benitez; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Christian F. Singer; Yen Tan; Edith Olah; Marie Navratilova; Lenka Foretova; Anne Marie Gerdes; Marie José Roos-Blom; Flora E. Van Leeuwen; Brita Arver; Håkan Olsson; Rita K. Schmutzler; Christoph Engel; Karin Kast; Kelly Anne Phillips; Mary Beth Terry; Roger L. Milne; David E. Goldgar; Matti A. Rookus; Nadine Andrieu; Douglas F. Easton

doi:10.1186/s13058-020-1247-4

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers

Nasim Mavaddat, Antonis C. Antoniou, Thea M. Mooij, Maartje J. Hooning, Bernadette A. Heemskerk-Gerritsen, Catherine Noguès, Lilian Laborde, Emmanuel Breysse, Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Olivier Caron, Emmanuelle Fourme-Mouret, Jean Pierre Fricker, Christine Lasset, Valérie Bonadona, Pascaline Berthet, Laurence Faivre, Elisabeth Luporsi, Véronique MariLaurence Gladieff, Paul Gesta, Hagay Sobol, François Eisinger, Catherine Noguès, Michel Longy, Catherine Dugast, Chrystelle Colas, Isabelle Coupier, Pascal Pujol, Carole Corsini, Alain Lortholary, Philippe Vennin, Claude Adenis, Tan Dat Nguyen, Capucine Delnatte, Julie Tinat, Isabelle Tennevet, Jean Marc Limacher, Christine Maugard, Yves Jean Bignon, Liliane Demange, Clotilde Penet, Hélène Dreyfus, Odile Cohen-Haguenauer, Laurence Venat-Bouvet, Dominique Leroux, Hélène Dreyfus, Hélène Zattara-Cannoni, Sandra Fert-Ferrer, Odile Bera, Catherine Noguès, Marion Gauthier-Villars, Olivier Caron, Paul Gesta, Pascal Pujol, Alain Lortholary, Steve Ellis, Daniel Barrowdale, Debra Frost, D. Gareth Evans, Louise Izatt, Julian Adlard, Ros Eeles, Carole Brewer, Marc Tischkowitz, Alex Henderson, Jackie Cook, Diana Eccles, F. B.L. Hogervorst, J. M. Collée, C. J. Van Asperen, A. R. Mensenkamp, M. G.E.M. Ausems, H. E.J. Meijers-Heijboer, K. Van Engelen, M. J. Blok, J. C. Oosterwijk, J. Verloop, E. Van Den Broek, Klaartje Van Engelen, Marian J.E. Mourits, Margreet G.E.M. Ausems, Linetta B. Koppert, John L. Hopper, Esther M. John, Wendy K. Chung, Irene L. Andrulis, Mary B. Daly, Saundra S. Buys, Javier Benitez, Trinidad Caldes, Anna Jakubowska, Jacques Simard, Christian F. Singer, Yen Tan, Edith Olah, Marie Navratilova, Lenka Foretova, Anne Marie Gerdes, Marie José Roos-Blom, Flora E. Van Leeuwen, Brita Arver, Håkan Olsson, Rita K. Schmutzler, Christoph Engel, Karin Kast, Kelly Anne Phillips, Mary Beth Terry, Roger L. Milne, David E. Goldgar, Matti A. Rookus, Nadine Andrieu, Douglas F. Easton

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

45 Citations (Scopus)

Résumé

Background: The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. Methods: A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. Results: There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. Conclusion: We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.

langue originale	Anglais
Numéro d'article	8
journal	Breast Cancer Research
Volume	22
Numéro de publication	1
Les DOIs	https://doi.org/10.1186/s13058-020-1247-4
état	Publié - 16 janv. 2020

Accès au document

10.1186/s13058-020-1247-4

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Mavaddat, N., Antoniou, A. C., Mooij, T. M., Hooning, M. J., Heemskerk-Gerritsen, B. A., Noguès, C., Laborde, L., Breysse, E., Stoppa-Lyonnet, D., Gauthier-Villars, M., Buecher, B., Caron, O., Fourme-Mouret, E., Fricker, J. P., Lasset, C., Bonadona, V., Berthet, P., Faivre, L., Luporsi, E., ... Easton, D. F. (2020). Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 22(1), Article 8. https://doi.org/10.1186/s13058-020-1247-4

@article{8a0334b5d5a742329827385efbe655bc,

title = "Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers",

abstract = "Background: The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. Methods: A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. Results: There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. Conclusion: We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.",

keywords = "BRCA1, BRCA2, Breast cancer, Mutation, Risk-reducing salpingo-oophorectomy",

author = "Nasim Mavaddat and Antoniou, {Antonis C.} and Mooij, {Thea M.} and Hooning, {Maartje J.} and Heemskerk-Gerritsen, {Bernadette A.} and Catherine Nogu{\`e}s and Lilian Laborde and Emmanuel Breysse and Dominique Stoppa-Lyonnet and Marion Gauthier-Villars and Bruno Buecher and Olivier Caron and Emmanuelle Fourme-Mouret and Fricker, {Jean Pierre} and Christine Lasset and Val{\'e}rie Bonadona and Pascaline Berthet and Laurence Faivre and Elisabeth Luporsi and V{\'e}ronique Mari and Laurence Gladieff and Paul Gesta and Hagay Sobol and Fran{\c c}ois Eisinger and Catherine Nogu{\`e}s and Michel Longy and Catherine Dugast and Chrystelle Colas and Isabelle Coupier and Pascal Pujol and Carole Corsini and Alain Lortholary and Philippe Vennin and Claude Adenis and Nguyen, {Tan Dat} and Capucine Delnatte and Julie Tinat and Isabelle Tennevet and Limacher, {Jean Marc} and Christine Maugard and Bignon, {Yves Jean} and Liliane Demange and Clotilde Penet and H{\'e}l{\`e}ne Dreyfus and Odile Cohen-Haguenauer and Laurence Venat-Bouvet and Dominique Leroux and H{\'e}l{\`e}ne Dreyfus and H{\'e}l{\`e}ne Zattara-Cannoni and Sandra Fert-Ferrer and Odile Bera and Catherine Nogu{\`e}s and Marion Gauthier-Villars and Olivier Caron and Paul Gesta and Pascal Pujol and Alain Lortholary and Steve Ellis and Daniel Barrowdale and Debra Frost and Evans, {D. Gareth} and Louise Izatt and Julian Adlard and Ros Eeles and Carole Brewer and Marc Tischkowitz and Alex Henderson and Jackie Cook and Diana Eccles and Hogervorst, {F. B.L.} and Coll{\'e}e, {J. M.} and {Van Asperen}, {C. J.} and Mensenkamp, {A. R.} and Ausems, {M. G.E.M.} and Meijers-Heijboer, {H. E.J.} and {Van Engelen}, K. and Blok, {M. J.} and Oosterwijk, {J. C.} and J. Verloop and {Van Den Broek}, E. and {Van Engelen}, Klaartje and Mourits, {Marian J.E.} and Ausems, {Margreet G.E.M.} and Koppert, {Linetta B.} and Hopper, {John L.} and John, {Esther M.} and Chung, {Wendy K.} and Andrulis, {Irene L.} and Daly, {Mary B.} and Buys, {Saundra S.} and Javier Benitez and Trinidad Caldes and Anna Jakubowska and Jacques Simard and Singer, {Christian F.} and Yen Tan and Edith Olah and Marie Navratilova and Lenka Foretova and Gerdes, {Anne Marie} and Roos-Blom, {Marie Jos{\'e}} and {Van Leeuwen}, {Flora E.} and Brita Arver and H{\aa}kan Olsson and Schmutzler, {Rita K.} and Christoph Engel and Karin Kast and Phillips, {Kelly Anne} and Terry, {Mary Beth} and Milne, {Roger L.} and Goldgar, {David E.} and Rookus, {Matti A.} and Nadine Andrieu and Easton, {Douglas F.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s).",

year = "2020",

month = jan,

day = "16",

doi = "10.1186/s13058-020-1247-4",

language = "English",

volume = "22",

journal = "Breast Cancer Research",

issn = "1465-5411",

number = "1",

}

Mavaddat, N, Antoniou, AC, Mooij, TM, Hooning, MJ, Heemskerk-Gerritsen, BA, Noguès, C, Laborde, L, Breysse, E, Stoppa-Lyonnet, D, Gauthier-Villars, M, Buecher, B, Caron, O, Fourme-Mouret, E, Fricker, JP, Lasset, C, Bonadona, V, Berthet, P, Faivre, L, Luporsi, E, Mari, V, Gladieff, L, Gesta, P, Sobol, H, Eisinger, F, Noguès, C, Longy, M, Dugast, C, Colas, C, Coupier, I, Pujol, P, Corsini, C, Lortholary, A, Vennin, P, Adenis, C, Nguyen, TD, Delnatte, C, Tinat, J, Tennevet, I, Limacher, JM, Maugard, C, Bignon, YJ, Demange, L, Penet, C, Dreyfus, H, Cohen-Haguenauer, O, Venat-Bouvet, L, Leroux, D, Dreyfus, H, Zattara-Cannoni, H, Fert-Ferrer, S, Bera, O, Noguès, C, Gauthier-Villars, M, Caron, O, Gesta, P, Pujol, P, Lortholary, A, Ellis, S, Barrowdale, D, Frost, D, Evans, DG, Izatt, L, Adlard, J, Eeles, R, Brewer, C, Tischkowitz, M, Henderson, A, Cook, J, Eccles, D, Hogervorst, FBL, Collée, JM, Van Asperen, CJ, Mensenkamp, AR, Ausems, MGEM, Meijers-Heijboer, HEJ, Van Engelen, K, Blok, MJ, Oosterwijk, JC, Verloop, J, Van Den Broek, E, Van Engelen, K, Mourits, MJE, Ausems, MGEM, Koppert, LB, Hopper, JL, John, EM, Chung, WK, Andrulis, IL, Daly, MB, Buys, SS, Benitez, J, Caldes, T, Jakubowska, A, Simard, J, Singer, CF, Tan, Y, Olah, E, Navratilova, M, Foretova, L, Gerdes, AM, Roos-Blom, MJ, Van Leeuwen, FE, Arver, B, Olsson, H, Schmutzler, RK, Engel, C, Kast, K, Phillips, KA, Terry, MB, Milne, RL, Goldgar, DE, Rookus, MA, Andrieu, N & Easton, DF 2020, 'Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers', Breast Cancer Research, VOL. 22, Numéro 1, 8. https://doi.org/10.1186/s13058-020-1247-4

TY - JOUR

T1 - Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk

T2 - An international prospective cohort of BRCA1 and BRCA2 mutation carriers

AU - Mavaddat, Nasim

AU - Antoniou, Antonis C.

AU - Mooij, Thea M.

AU - Hooning, Maartje J.

AU - Heemskerk-Gerritsen, Bernadette A.

AU - Noguès, Catherine

AU - Laborde, Lilian

AU - Breysse, Emmanuel

AU - Stoppa-Lyonnet, Dominique

AU - Gauthier-Villars, Marion

AU - Buecher, Bruno

AU - Caron, Olivier

AU - Fourme-Mouret, Emmanuelle

AU - Fricker, Jean Pierre

AU - Lasset, Christine

AU - Bonadona, Valérie

AU - Berthet, Pascaline

AU - Faivre, Laurence

AU - Luporsi, Elisabeth

AU - Mari, Véronique

AU - Gladieff, Laurence

AU - Gesta, Paul

AU - Sobol, Hagay

AU - Eisinger, François

AU - Noguès, Catherine

AU - Longy, Michel

AU - Dugast, Catherine

AU - Colas, Chrystelle

AU - Coupier, Isabelle

AU - Pujol, Pascal

AU - Corsini, Carole

AU - Lortholary, Alain

AU - Vennin, Philippe

AU - Adenis, Claude

AU - Nguyen, Tan Dat

AU - Delnatte, Capucine

AU - Tinat, Julie

AU - Tennevet, Isabelle

AU - Limacher, Jean Marc

AU - Maugard, Christine

AU - Bignon, Yves Jean

AU - Demange, Liliane

AU - Penet, Clotilde

AU - Dreyfus, Hélène

AU - Cohen-Haguenauer, Odile

AU - Venat-Bouvet, Laurence

AU - Leroux, Dominique

AU - Dreyfus, Hélène

AU - Zattara-Cannoni, Hélène

AU - Fert-Ferrer, Sandra

AU - Bera, Odile

AU - Noguès, Catherine

AU - Gauthier-Villars, Marion

AU - Caron, Olivier

AU - Gesta, Paul

AU - Pujol, Pascal

AU - Lortholary, Alain

AU - Ellis, Steve

AU - Barrowdale, Daniel

AU - Frost, Debra

AU - Evans, D. Gareth

AU - Izatt, Louise

AU - Adlard, Julian

AU - Eeles, Ros

AU - Brewer, Carole

AU - Tischkowitz, Marc

AU - Henderson, Alex

AU - Cook, Jackie

AU - Eccles, Diana

AU - Hogervorst, F. B.L.

AU - Collée, J. M.

AU - Van Asperen, C. J.

AU - Mensenkamp, A. R.

AU - Ausems, M. G.E.M.

AU - Meijers-Heijboer, H. E.J.

AU - Van Engelen, K.

AU - Blok, M. J.

AU - Oosterwijk, J. C.

AU - Verloop, J.

AU - Van Den Broek, E.

AU - Van Engelen, Klaartje

AU - Mourits, Marian J.E.

AU - Ausems, Margreet G.E.M.

AU - Koppert, Linetta B.

AU - Hopper, John L.

AU - John, Esther M.

AU - Chung, Wendy K.

AU - Andrulis, Irene L.

AU - Daly, Mary B.

AU - Buys, Saundra S.

AU - Benitez, Javier

AU - Caldes, Trinidad

AU - Jakubowska, Anna

AU - Simard, Jacques

AU - Singer, Christian F.

AU - Tan, Yen

AU - Olah, Edith

AU - Navratilova, Marie

AU - Foretova, Lenka

AU - Gerdes, Anne Marie

AU - Roos-Blom, Marie José

AU - Van Leeuwen, Flora E.

AU - Arver, Brita

AU - Olsson, Håkan

AU - Schmutzler, Rita K.

AU - Engel, Christoph

AU - Kast, Karin

AU - Phillips, Kelly Anne

AU - Terry, Mary Beth

AU - Milne, Roger L.

AU - Goldgar, David E.

AU - Rookus, Matti A.

AU - Andrieu, Nadine

AU - Easton, Douglas F.

PY - 2020/1/16

Y1 - 2020/1/16

N2 - Background: The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. Methods: A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. Results: There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. Conclusion: We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.

AB - Background: The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. Methods: A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. Results: There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. Conclusion: We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.

KW - BRCA1

KW - BRCA2

KW - Breast cancer

KW - Mutation

KW - Risk-reducing salpingo-oophorectomy

UR - http://www.scopus.com/inward/record.url?scp=85078031432&partnerID=8YFLogxK

U2 - 10.1186/s13058-020-1247-4

DO - 10.1186/s13058-020-1247-4

M3 - Article

C2 - 31948486

AN - SCOPUS:85078031432

SN - 1465-5411

VL - 22

JO - Breast Cancer Research

JF - Breast Cancer Research

IS - 1

M1 - 8

ER -